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The National Lung Screening Trial was conducted to determine whether three annual screenings (rounds T0, T1, and T2) with low-dose helical computed tomography (CT), as compared with chest radiography, could reduce mortality from lung
cancer. We present detailed findings from the first two incidence screenings
(rounds T1 and T2).
Methods

We evaluated the rate of adherence of the participants to the screening protocol, the
results of screening and downstream diagnostic tests, features of the lung-cancer
cases, and first-line treatments, and we estimated the performance characteristics
of both screening methods.
Results

At the T1 and T2 rounds, positive screening results were observed in 27.9% and
16.8% of participants in the low-dose CT group and in 6.2% and 5.0% of participants in the radiography group, respectively. In the low-dose CT group, the sensitivity was 94.4%, the specificity was 72.6%, the positive predictive value was 2.4%, and
the negative predictive value was 99.9% at T1; at T2, the positive predictive value
increased to 5.2%. In the radiography group, the sensitivity was 59.6%, the specificity was 94.1%, the positive predictive value was 4.4%, and the negative predictive
value was 99.8% at T1; both the sensitivity and the positive predictive value increased at T2. Among lung cancers of known stage, 87 (47.5%) were stage IA and
57 (31.1%) were stage III or IV in the low-dose CT group at T1; in the radiography
group, 31 (23.5%) were stage IA and 78 (59.1%) were stage III or IV at T1. These
differences in stage distribution between groups persisted at T2.
Conclusions

Low-dose CT was more sensitive in detecting early-stage lung cancers, but its measured positive predictive value was lower than that of radiography. As compared
with radiography, the two annual incidence screenings with low-dose CT resulted
in a decrease in the number of advanced-stage cancers diagnosed and an increase
in the number of early-stage lung cancers diagnosed. (Funded by the National Cancer Institute; NLST ClinicalTrials.gov number, NCT00047385.)
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RESULTS OF INCIDENCE Screening IN THE NLST

T

he National Lung Screening Trial
(NLST) was a randomized trial of lungcancer–specific mortality among participants in an asymptomatic high-risk cohort who
underwent screening with the use of low-dose
helical computed tomography (CT) as compared
with screening with the use of single-view posteroanterior chest radiography. The NLST showed
a 20% relative reduction in mortality from lung
cancer with three rounds of low-dose CT screening (rounds T0, T1, and T2) as compared with
radiography.1 In this article, we present more detailed findings from the two incidence screenings (rounds T1 and T2), including information
on rates of positive screening tests, performance
characteristics of the screening tests, diagnostic
follow-up of positive screening results, numbers
and characteristics of the lung cancers detected,
and first-line treatments. Detailed findings from
the prevalence screening (T0) are reported separately.2

Me thods
Trial Oversight

The design and eligibility criteria of the NLST, as
well as demographic characteristics of the NLST
participants, have been described in detail previously.3,4 Enrollment occurred from August 2002
through April 2004, and screening occurred
from August 2002 through September 2007. Participants were followed for events that occurred
through December 31, 2009. A total of 53,454
participants who were at risk for lung cancer
were randomly assigned to three annual screenings with either low-dose CT or radiography. The
study protocol was approved by the institutional
review board at each of 33 screening centers, and
written informed consent was obtained from
each participant before randomization.
Screening

Acquisition factors and measures to control image quality for both low-dose CT and radiographic
screenings were standardized throughout the
trial.5 Images were interpreted by individual radiologists on soft-copy display stations without
computer-assisted image analysis. A positive lowdose CT screening test was defined as the finding of one or more indeterminate (noncalcified)
nodules measuring at least 4 mm in the longest
diameter or, less commonly, mediastinal masses,
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pleural disease, or atelectasis of more than one
segment. A positive radiographic screening test
was defined as the finding of a noncalcified nodule of any size or another abnormality potentially related to lung cancer. At the discretion of the
radiologist, nodules at incidence screenings that
showed no change in growth or consistency from
those detected at the previous screening could be
classified as “positive, stable”; nodules that were
stable across all three annual screenings could
be classified as “positive, stable” or “negative.”
Outcomes and Follow-up

The primary end point of the NLST was lungcancer–specific mortality. Data on participants
were obtained by means of medical-record abstraction and included the types and results of
downstream diagnostic tests; histologic features,
grade, and stage of lung cancers diagnosed; histologic features of other cancers; details of firstline treatments for lung cancer; and deaths from
all causes. The methods for the histopathological
classification of lung cancer, lung-cancer staging,
and determination of vital status and cause of
death have been described previously.1,6-9
Statistical Analysis

We compared the two screening groups with respect to adherence of the participants to the testing protocol, screening results, types of diagnostic procedures and results, and initial treatment
information. Measures of diagnostic and predictive accuracy at the T1 and T2 rounds were derived with the use of data only from participants
who had adequate screening examinations in the
respective rounds and for whom lung-cancer status was known. For each dichotomous (positive
vs. negative) screening result, lung cancer was
classified as present or absent at the time of the
screening on the basis of specific rules related to
the timing of lung-cancer diagnosis relative to
screening intervals and diagnostic testing (see the
Supplementary Appendix, available with the full
text of this article at NEJM.org). The sensitivity,
specificity, positive predictive value, and negative
predictive value were calculated according to accepted definitions, and confidence intervals were
calculated with the use of bootstrapping.10 Screenings of participants with unknown lung-cancer
status were excluded from calculations of screening test performance. We calculated the confidence intervals for incidence ratios assuming a
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Poisson distribution for the number of events
and a normal distribution of the logarithm of the
ratio, using asymptotic methods. All tabulations
were performed with the use of SAS/STAT software, version 9.1 of the SAS System for Unix or
version 9.2 for PC (SAS Institute).

R e sult s
Screening

At the T1 screening, 94.0% of eligible participants
in the low-dose CT group (24,715 of 26,285) and
91.2% of eligible participants in the radiography
group (24,089 of 26,410) underwent screening
(Table 1). T1 screening results were positive in
27.9% of the participants who were screened
in the low-dose CT group (6901 of 24,715) and
in 6.2% of the participants who were screened in
the radiography group (1482 of 24,089). A total of
186 participants received a diagnosis of lung cancer in the low-dose CT group at T1: 168 of 6901
participants with positive screening results, 10
of 17,814 participants with negative screening
results, 6 of 1570 participants who were not
screened at T1, and 2 of 437 ineligible participants
with lung cancers that were first diagnosed during the T1 screening year (Fig. 1A). In the radiography group, 133 participants received a diagnosis
of lung cancer at T1: 65 of 1482 participants with
positive screening results, 44 of 22,607 participants with negative screening results, 21 of 2321
participants who were not screened, and 3 of 322
ineligible participants with lung cancers that
were diagnosed during the T1 screening year.
The sensitivity of low-dose CT was 94.4% (95%
confidence interval [CI], 90.8 to 97.6), the specificity was 72.6% (95% CI, 72.0 to 73.1), the positive predictive value was 2.4% (95% CI, 2.1 to
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2.8), and the negative predictive value was 99.9%
(95% CI, 99.9 to 100.0) (Table S1 in the Supplementary Appendix). The sensitivity of radiography was 59.6% (95% CI, 50.0 to 69.0), the specificity was 94.1% (95% CI, 93.8 to 94.4), the
positive predictive value was 4.4% (95% CI, 3.3 to
5.5), and the negative predictive value was 99.8%
(95% CI, 99.7 to 99.9).
At the T2 screening, 92.9% of eligible participants in the low-dose CT group (24,102 of
25,942) and 89.4% of eligible participants in the
radiography group (23,346 of 26,110) underwent
screening (Fig. 1B and Table 1). T2 screening
results were positive in 16.8% of persons who
were screened in the low-dose CT group (4054 of
24,102) and in 5.0% of the persons who were
screened in the radiography group (1174 of
23,346). A total of 237 participants received a
diagnosis of lung cancer at T2 in the low-dose
CT group: 211 of 4054 participants with positive
screening results, 16 of 20,048 participants with
negative screening results, 7 of 1840 participants
who were not screened at T2, and 3 of 780 ineligible participants with lung cancers that were
diagnosed during the T2 screening year (Fig.
1B). In the radiography group, 144 participants
received a diagnosis of lung cancer at T2: 78 of
1174 participants with positive screening results,
44 of 22,172 participants with negative screening results, 18 of 2764 participants who were not
screened, and 4 of 622 participants who were
ineligible for the T2 screening but received a
diagnosis of lung cancer during the T2 screening year (Fig. 1B). The sensitivity of low-dose CT
was 93.0% (95% CI, 89.7 to 96.3), the specificity
was 83.9% (95% CI, 83.4 to 84.3), the positive
predictive value was 5.2% (95% CI, 4.6 to 5.9),
and the negative predictive value was 99.9%

Table 1. Screening Eligibility, Compliance, and Rates of Positive Screening Tests According to Screening Round
and Study Group.
Screening
Round

922

Low-Dose CT
Eligible for
Screening

Chest Radiography

Screened

Positive
Result

Eligible for
Screening

Screened

Positive
Result

no.

no.
(% of eligible)

no.
(% of screened)

no.

no.
(% of eligible)

no.
(% of screened)

T1

26,285

24,715 (94.0)

6901 (27.9)

26,410

24,089 (91.2)

1482 (6.2)

T2

25,942

24,102 (92.9)

4054 (16.8)

26,110

23,346 (89.4)

1174 (5.0)
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(95% CI, 99.9 to 100.0) (Table S1 in the Supplementary Appendix). The sensitivity of radiography was 63.9% (95% CI, 55.2 to 72.1), the specificity was 95.3% (95% CI, 95.0 to 95.6), the
positive predictive value was 6.7% (95% CI, 5.2 to
8.2), and the negative predictive value was 99.8%
(95% CI, 99.7 to 99.9).
The rates of positive screening tests in both
groups decreased at the T2 screening, primarily
because abnormalities that were stable across all
three rounds could be categorized as negative
screening results (Table 1). Data on lung-cancer
status according to the participants’ age, sex,
and race or ethnic group are provided in Tables
S2a and S2b in the Supplementary Appendix. In
both the low-dose CT and radiography groups,
43% of participants who underwent incidence
screening were 55 to 59 years of age at study
entry, but the rates of lung cancer among participants in this age group were the lowest (in the
low-dose CT group, 0.4% at the T1 screening and
0.7% at the T2 screening, and in the radiography
group, 0.3% at both the T1 and T2 screenings).
Follow-up of Positive Results

Information on diagnostic follow-up of positive
screening results was available for the majority of
participants in both groups at both screening
rounds (Tables S3a and S3b in the Supplementary
Appendix). Beyond office visits and physical
examinations, imaging examinations, including
diagnostic chest CT and 18F-fluorodeoxyglucose–
positron-emission tomography (FDG-PET), were
the most commonly performed procedures for
follow-up of positive tests in both groups and at
both screening rounds. FDG-PET was performed
much more frequently in participants with a lungcancer diagnosis than in those with no lung cancer.
In the low-dose CT group, both surgical and bronchoscopic interventional procedures were performed more commonly than percutaneous biopsies in both participants with and those without
lung-cancer diagnoses; the frequencies of these
interventional procedures were more evenly distributed in the radiography group. Among participants in the low-dose CT group who underwent
thoracotomy because of positive screening results,
the proportion in whom lung cancer was not diagnosed was 18.9% at the T1 screening and 15.9%
at the T2 screening. The respective proportions in
the radiography group were 11.4% and 13.6%.

n engl j med 369;10

Relationship of Nodule Size to Lung Cancer

At the T1 screening, 161 of 168 CT-detected lung
cancers (95.8%) and 60 of 65 radiography-detected
lung cancers (92.3%) were diagnosed on the basis of an observed lung nodule or mass (Table 2).
Among patients with lung cancers that were diagnosed with the use of low-dose CT screening at
T1, 58 (34.5%) had nodules that were 4 to 10 mm
in diameter, 74 (44.0%) had nodules that were 11
to 20 mm, 20 (11.9%) had nodules that were 21
to 30 mm, and 8 (4.8%) had masses larger than
30 mm. The positive predictive value for the detection of a nodule of any size with the use of
low-dose CT at T1 was 2.4%, but it increased to
58.2% for positive screening results with subsequent biopsy. For nodules that were 4 to 6 mm
diameter, the positive predictive value at T1 was
0.3%. In the radiography group, the largest nodule
or mass observed among 65 lung cancers detected
at the T1 screening was 4 to 10 mm in diameter
in 9 participants (13.8%), 11 to 20 mm in 22 participants (33.8%), 21 to 30 mm in 16 participants
(24.6%), and more than 30 mm in 10 participants (15.4%). The positive predictive value for
the detection of a nodule of any size at the T1
screening in the radiography group was 4.4%,
but it increased to 67.4% for positive screening
results with subsequent biopsy. In both groups,
the positive predictive value for detection of a
nodule increased as the nodule size increased
from 4 to 30 mm. In the radiography group, the
positive predictive value for nodules smaller than
4 mm was relatively high; it is unclear whether
these nodules corresponded to a lung cancer or
prompted follow-up assessments that led to an
ultimate diagnosis of lung cancer, although the
latter explanation is more likely. In both groups,
detection of masses larger than 30 mm had a
slightly decreased positive predictive value relative
to the detection of nodules that were 21 to 30 mm,
probably because pneumonia was interpreted as
a positive screening result.
In both groups, the proportions of cancers
associated with a lung nodule or mass at the T2
screening were similar to those seen at the T1
screening (Table 3). At T2, the positive predictive
value for detection of a nodule was 5.2% on lowdose CT and 6.4% on radiographic screening;
the corresponding positive predictive values for
detection of nodules that were 4 to 6 mm in diameter were 0.7% and 2.5%. With low-dose CT,
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A T1 Screening
53,454 Participants underwent randomization

26,722 Were assigned to low-dose
CT screening

26,732 Were assigned to chest
radiographic screening

437 Were not eligible
161 Died
276 Received diagnosis of
lung cancer before
screening

322 Were not eligible
144 Died
178 Received diagnosis of
lung cancer before
screening

26,285 Were eligible

26,410 Were eligible

2321 Were not screened
2015 Declined to participate
238 Withdrew from study
18 Underwent incorrect
screening
7 Had inadequate screening
43 Had other reasons

1570 Were not screened
1383 Declined to participate
153 Withdrew from study
9 Underwent incorrect
screening
2 Had inadequate screening
23 Had other reasons

24,715 Were screened

6 Had lung cancer

24,089 Were screened

17,814 Tested negative
for lung cancer

6901 Tested positive
for lung cancer

1482 Tested positive
for lung cancer

22,607 Tested negative
for lung cancer

17,788 Did not have
lung cancer
10 Had lung cancer
16 Had unknown
lung-cancer status

6728 Did not have
lung cancer
168 Had lung cancer
5 Had unknown
lung-cancer status

1416 Did not have
lung cancer
65 Had lung cancer
1 Had unknown
lung-cancer status

22,521 Did not have
lung cancer
44 Had lung cancer
42 Had unknown
lung-cancer status

21 Had lung cancer

Figure 1. Randomization and Follow-up of the Study Participants.
Panel A shows randomization and follow-up for the T1 screening. During the T1 study year, 2 of 437 ineligible participants in the low-dose
computed tomography (CT) group and 3 of 322 ineligible participants in the radiography group received a diagnosis of lung cancer (data
not shown). Panel B shows randomization and follow-up for the T2 screening. During the T2 study year, 3 of 780 ineligible participants in
the low-dose CT group and 4 of 622 ineligible participants in the radiography group received a diagnosis of lung cancer (data not shown).

the positive predictive value increased with increasing nodule size at T2; this was not the case
with radiography because of a decrease in the
positive predictive value for masses larger than
30 mm and two cases in which nodules smaller
than 4 mm were associated with lung cancer. As
expected, in both groups, detection of stable
nodules at T2 was less predictive of lung cancer

924
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than detection of new nodules. For positive
screening tests with subsequent biopsy, the positive predictive value increased to 65.8% with lowdose CT and to 67.9% with radiography. At both
the T1 and T2 screenings, there was no clear
relationship between nodule size and stage of
non–small-cell lung cancer in either group (Table
S4 in the Supplementary Appendix).
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B T2 Screening
53,454 Participants underwent randomization

26,722 Were assigned to low-dose
CT screening

26,732 Were assigned to chest
radiographic screening

780 Were not eligible
341 Died
439 Received diagnosis of
lung cancer before
screening

622 Were not eligible
342 Died
280 Received diagnosis of
lung cancer before
screening

25,942 Were eligible

26,110 Were eligible

2764 Were not screened
2372 Declined to participate
325 Withdrew from study
14 Underwent incorrect
screening
6 Had inadequate screening
47 Had other reasons

1840 Were not screened
1577 Declined to participate
224 Withdrew from study
12 Underwent incorrect
screening
1 Had inadequate screening
26 Had other reasons

24,102 Were screened

7 Had lung cancer

23,346 Were screened

20,048 Tested negative
for lung cancer

4054 Tested positive
for lung cancer

1174 Tested positive
for lung cancer

22,172 Tested negative
for lung cancer

19,968 Did not have
lung cancer
16 Had lung cancer
64 Had unknown
lung-cancer status

3838 Did not have
lung cancer
211 Had lung cancer
5 Had unknown
lung-cancer status

1094 Did not have
lung cancer
78 Had lung cancer
2 Had unknown
lung-cancer status

22,067 Did not have
lung cancer
44 Had lung cancer
61 Had unknown
lung-cancer status

Stage Distribution and Treatment of Lung
Cancer

At the T1 screening, the clinical or pathological
stage was known in 183 of 186 participants in
the low-dose CT group (Table 4). Among participants with lung cancer of a known stage, 87 had
stage IA cancer (47.5%); 39 had stage IB, IIA, or
IIB cancer (21.3%); and 57 had stage III or IV
cancer (31.1%). Among participants in the radiography group who received a lung-cancer diagnosis at T1, the stage was known in 132 of 133
participants; 31 had stage IA cancer (23.5%); 23 had
stage IB, IIA, or IIB cancer (17.4%); and 78 had

n engl j med 369;10

18 Had lung cancer

stage III or IV cancer (59.1%). Stage distributions
at T2 were similar to those at T1 in each group.
In the low-dose CT group, the increase in
early-stage lung cancers was associated with a
decrease in late-stage lung cancers. Over the
course of the trial, the incidence of stage IV lung
cancer was 138 cases per 100,000 person-years
in the low-dose CT group, as compared with 204
cases per 100,000 person-years in the radiography group (rate ratio, 0.68; 95% CI, 0.57 to 0.80).
The distribution of stage according to screening result was fairly consistent between the T1
and T2 screenings in the low-dose CT group. At
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161 (95.8)

With noncalcified
nodule or mass

n engl j med 369;10

8 (4.8)

1 (0.6)

>30 mm

Unknown

nejm.org

11 (6.5)

Pleural thickening or
effusion

427 (6.3)

50 (0.7)

151 (2.2)

77 (1.1)

0

0

1 (20.0)

0

0

0

0

0

4 (80.0)

1 (20.0)

0

5 (100.0)

0

5

438 (6.3)

51 (0.7)

175 (2.5)

80 (1.2)

20 (0.3)

55 (0.8)

114 (1.7)

815 (11.8)

1959 (28.4)

3822 (55.4)

1 (0)

6786 (98.3)

287 (4.2)

6901

2.5

2.0

13.2

3.8

5.0

14.5

17.5

9.1

2.4

0.3

0.0

2.4

58.2

2.4

1.2–4.0

0.0–6.4

8.5–18.4

0.0–8.5

0.0–16.7

6.2–24.6

10.6–24.6

7.0–11.1

1.7–3.0

0.2–0.5

0.0–0.0

2.0–2.7

52.7–64.0

2.1–2.8

percent

PPV
Range

2 (3.1)

2 (3.1)

8 (12.3)

1 (1.5)

2 (3.1)

10 (15.4)

16 (24.6)

22 (33.8)

8 (12.3)

1 (1.5)

1 (1.5)

60 (92.3)

64 (98.5)

65

yes

unknown

98 (6.9)

30 (2.1)

25 (1.8)

12 (0.8)

121 (8.5)

43 (3.0)

46 (3.2)

321 (22.7)

433 (30.6)

304 (21. 5)

28 (2.0)

1296 (91.5)

31 (2.2)

1416

1 (100.0)

0

0

0

0

0

1 (100.0)

0

0

0

0

1 (100.0)

0

1

number (percent)

no

Confirmed Lung Cancer

101 (6.8)

32 (2.2)

33 (2.2)

13 (0.9)

123 (8.3)

53 (3.6)

63 (4.3)

343 (23.1)

441 (29.8)

305 (20.6)

29 (2.0)

1357 (91.6)

95 (6.4)

1482

Total

2.0

6.3

24.2

7.7

1.6

18.9

25.8

6.4

1.8

0.3

3.4

4.4

67.4

4.4

PPV†

0.0–5.4

0.0–15.0

10.1–41.3

0.0–26.4

0.0–4.4

9.0–30.6

15.2–36.8

4.0–9.3

0.7–3.2

0.0–1.1

0.0–11.7

3.4–5.6

56.8–76.7

3.4–5.5

percent

PPV
Range

* The cases of confirmed lung cancer do not include the following cancers diagnosed during the T1 study year: 32 in participants who did not undergo screening at T1, 10 in participants
with negative results of low-dose CT screening at T1, and 44 in participants with negative results of radiographic screening at T1.
† PPV is defined as the proportion of confirmed lung cancers among the participants with positive screening tests who had a known lung-cancer status.
‡ Nodule size refers to the diameter of the largest nodule recorded on the screening examination.

1 (0.6)

23 (13.7)

Noncalcified hilar
or mediastinal
adenopathy or
mass

Consolidation

3 (1.8)

19 (0.3)

47 (0.7)

94 (1.4)

741 (11.0)

1909 (28.4)

3809 (56.6)

1 (0)

6620 (98.4)

120 (1.8)

6728

PPV†

Chest Radiography

of

Atelectasis, segmental
or more extensive

unknown

number (percent)

no

Total

Low-Dose CT

n e w e ng l a n d j o u r na l

Other findings

74 (44.0)

20 (11.9)

21–30 mm

7–10 mm

11–20 mm

12 (7.1)

46 (27.4)

4–6 mm

0

<4 mm

Size of nodule or mass‡

167 (99.4)

168

yes

Confirmed Lung Cancer

With subsequent
biopsy

Positive screening result

Variable

Table 2. Frequency of Positive Screening Results and Positive Predictive Value (PPV) at T1 Screening, According to Study Group.*
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206 (97.6)

15 (7.1)
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107 (2.8)

2216 (57.7)
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86 (40.8)
23 (10.9)
20 (9.5)
1 (0.5)

11–20 mm

21–30 mm

>30 mm

Unknown

september 5, 2013

278 (7.2)

35 (0.9)

78 (2.0)

90 (2.3)

9 (0.2)

41 (1.1)

77 (2.0)

502 (13.1)

1 (20.0)

0

0

1 (20.0)

0

1 (20.0)

0

0

1 (20.0)

1 (20.0)

0

3 (60.0)

0

1 (20.0)

4 (80.0)

5

294 (7.3)

39 (1.0)

97 (2.4)

95 (2.3)

10 (0.2)

62 (1.5)

100 (2.5)

588 (14.5)

1131 (27.9)

2023 (49.9)

7 (0.2)

3921 (96.7)

313 (7.7)

2232 (55.1)

1822 (44.9)

4054

Total

5.1

10.3

19.6

4.3

10.0

32.8

23.0

14.6

5.1

0.7

0

5.2

65.8

0.7

10.8

5.2

PPV†

2.9–7.9

2.2–20.6

12.1–28.1

0.9–8.8

0.0–33.3

21.0–45.1

14.1–31.7

11.7–17.5

4.0–6.4

0.4–1.1

0.0–0.0

4.5–5.9

60.2–71.1

0.4–1.0

9.4–12.2

4.5–6.0

percent

PPV
Range

6 (7.7)

2 (2.6)

7 (9.0)

3 (3.8)

8 (10.3)

2 (2.6)

19 (24.4)

22 (28.2)

9 (11.5)

5 (6.4)

2 (2.6)

67 (85.9)

74 (94.9)

4 (5.1)

74 (94.9)

78

yes

unknown

80 (7.3)

34 (3.1)

33 (3.0)

21 (1.9)

100 (9.1)

22 (2.0)

47 (4.3)

263 (24.0)

335 (30.6)

197 (18.0)

11 (1.0)

975 (89.1)

35 (3.2)

229 (20.9)

865 (79.1)

1094

109 (9.3)

234 (19.9)

940 (80.1)

1174

Total

0

0

0

0

1 (50.0)

1 (50.0)

0

0

0

0

0

86 (7.3)

36 (3.1)

40 (3.4)

24 (2.0)

109 (9.3)

25 (2.1)

66 (5.6)

285 (24.3)

344 (29.3)

202 (17.2)

13 (1.1)

2 (100.0) 1044 (88.9)

0

1 (50.0)

1 (50.0)

2

number (percent)

no

Confirmed Lung Cancer

Chest Radiography

7.0

5.6

17.5

12.5

7.4

8.3

28.8

7.7

2.6

2.5

15.4

6.4

67.9

1.7

7.9

6.7

PPV†

2.1–12.6

0.0–14.3

5.8–30.4

0.0–28.6

3.0–12.5

0.0–20.9

18.2–40.0

4.9–10.6

1.1–4.4

0.5–4.7

0.0–37.5

5.0–8.0

59.0–76.3

0.4–3.6

6.3–9.5

5.4–8.0

percent

PPV
Range

* The cases of confirmed lung cancer do not include the following cancers diagnosed during the T2 study year: 32 in participants who did not undergo screening at T2, 16 in participants
with negative results of low-dose CT screening at T2, and 44 in participants with negative results of radiographic screening at T2.
† PPV is defined as the proportion of confirmed lung cancers among the participants with positive screening tests who had a known lung-cancer status.
‡ Nodule size refers to the diameter of the largest nodule recorded on the screening examination.

4 (1.9)
15 (7.1)

Pleural thickening or effusion

19 (9.0)

Noncalcified hilar or mediastinal adenopathy
or mass

Consolidation

4 (1.9)

Atelectasis, segmental or
more extensive

Other findings

58 (27.5) 1072 (27.9)

7–10 mm

2007 (52.3)

15 (7.1)

4–6 mm

7 (0.2)

0

<4 mm

Size of nodule or mass‡

unknown

number (percent)

no

196 (92.9) 1622 (42.3)

211

yes

Confirmed Lung Cancer

Low-Dose Computed Tomography

With noncalcified nodule 203 (96.2) 3715 (96.8)
or mass

With subsequent biopsy

Stable finding

New finding

Positive screening result

Variable

Table 3. Frequency of Positive Screening Results and Positive Predictive Value at T2 Screening, According to Study Group.*
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Table 4. Stage of Lung Cancers, According to Screening Round, Study Group, and Screening Result.*
Screening Round
and Stage

Low-Dose CT
Positive

Negative

No
Screening

Chest Radiography
Total

Positive

Negative

No
Screening

Total

number/total number (percent)
T1 screening round
Stage IA

86/165 (52.1)

1/10 (10.0)

Stage IB

18/165 (10.9)

1/10 (10.0)

Stage IIA

11/165 (6.7)

0

Stage IIB

6/165 (3.6)

0

0
2/8 (25.0)
0
1/8 (12.5)

23/65 (35.4)

6/43 (14.0)

2/24 (8.3)

31/132 (23.5)

9/65 (13.8)

1/43 (2.3)

1/24 (4.2)

11/132 (8.3)

11/183 (6.0)

4/65 (6.2)

2/43 (4.7)

1/24 (4.2)

7/132 (5.3)

7/183 (3.8)

3/65 (4.6)

1/43 (2.3)

1/24 (4.2)

5/132 (3.8)
14/132 (10.6)

Stage IIIA

13/165 (7.9)

1/10 (10.0)

14/183 (7.7)

6/65 (9.2)

6/43 (14.0)

2/24 (8.3)

Stage IIIB

13/165 (7.9)

4/10 (40.0)

2/8 (25.0)

19/183 (10.4)

2/65 (3.1)

6/43 (14.0)

4/24 (16.7) 12/132 (9.2)

Stage IV

18/165 (10.9)

3/10 (30.0)

3/8 (37.5)

24/183 (13.1)

18/65 (27.7)

21/43 (48.8)

13/24 (54.2) 52/132 (39.4)

Unknown†

3/168 (1.8)

0

0

87/183 (47.5)
21/183 (11.5)

0

3/186 (1.6)

0

1/44 (2.3)

0

1/133 (0.8)

T2 screening round
Stage IA

113/204 (55.4)

Stage IB

28/204 (13.7)

Stage IIA

8/204 (3.9)

Stage IIB

3/204 (1.5)

2/16 (12.5)
0
0
2/16 (12.5)

27/77 (35.1)

4/44 (9.1)

10/77 (13.0)

3/44 (6.8)

0

8/230 (3.5)

0

5/230 (2.2)

0

7/77 (9.1)
0

0
3/44 (6.8)

4/22 (18.2) 35/143 (24.5)
0
2/22 (9.1)
0

13/143 (9.1)
9/143 (6.3)
3/143 (2.1)

Stage IIIA

15/204 (7.4)

15/230 (6.5)

10/77 (13.0)

7/44 (15.9)

1/22 (4.5)

Stage IIIB

15/204 (7.4)

4/16 (25.0)

1/10 (10.0) 20/230 (8.7)

10/77 (13.0)

6/44 (13.6)

5/22 (22.7) 21/143 (14.7)

Stage IV

22/204 (10.8)

8/16 (50.0)

5/10 (50.0) 35/230 (15.2)

13/77 (16.9)

21/44 (47.7)

10/22 (45.5) 44/143 (30.8)

Unknown‡

7/211 (3.3)

0

1/10 (10.0) 116/230 (50.4)
3/10 (30.0) 31/230 (13.5)

0

0

7/237 (3.0)

1/78 (1.3)

0

0

18/143 (12.6)

1/144 (0.7)

* Cancer-stage classification was based on the sixth edition of the Cancer Staging Manual of the American Joint Committee on Cancer.7 The
denominators for cancer stage were the total number of lung cancers of known stage in each screening-result category.
† The lung cancers of unknown stage at the T1 screening round included 4 cancers with stage information that could not be classified.
‡ The lung cancers of unknown stage at the T2 screening round included 2 carcinoids, 1 occult carcinoma, 1 with no evidence of malignancy,
and 4 with stage information that could not be classified.

both T1 and T2, the majority of stage IA lung
cancers were detected in participants with screening results that were positive on low-dose CT;
lung cancers diagnosed in participants with
negative results (interval cancers) were predominantly advanced-stage cancers. In the radiography group, as compared with the low-dose CT
group, lung cancers detected in participants with
positive results were more equally distributed
among early, intermediate, and advanced stages.
Of small-cell lung cancers detected by means of
low-dose CT, 92.3% of those detected at T1 and
66.7% of those detected at T2 were late-stage
cancers; corresponding percentages in the radiography group were 42.9% and 66.7% (data not
shown). For lung cancers at each stage, participants in the low-dose CT and radiography
groups received similar treatment (Tables S5a
and S5b in the Supplementary Appendix).
928
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Histologic Characteristics of Diagnosed
Lung Cancers

The most common histologic types of lung cancer in both screening groups and at both screenings were adenocarcinoma (at T1, 36.6% of cancers diagnosed in the low-dose CT group and
32.8% of those diagnosed in the radiography
group; at T2, 34.9% in the low-dose CT group
and 33.1% in the radiography group) and squamous-cell carcinoma (at T1, 21.0% of cancers
diagnosed in the low-dose CT group and 22.9%
of those diagnosed in the radiography group; at
T2, 26.0% in the low-dose CT group and 23.9%
in the radiography group) (Table S6 in the Supplementary Appendix).
In the low-dose CT group, lung cancers characterized as bronchioloalveolar-cell carcinoma
were predominantly diagnosed after a positive
screening and accounted for 17.3% and 13.3% of
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all lung cancers detected on positive screening at
T1 and T2, respectively. Bronchioloalveolar-cell
carcinoma included pure adenocarcinoma in situ,
minimally invasive adenocarcinoma, and invasive adenocarcinoma, lepidic predominant (i.e.,
neoplastic cell growth restricted to preexisting
alveolar structures); these histologic subtypes
are now classified separately.11 Few bronchioloalveolar-cell carcinomas were diagnosed in the
radiography group, probably because they are
difficult to discern on planar imaging. The frequency of small-cell carcinoma was similar in
the low-dose CT and radiography groups at both
screenings, but in the low-dose CT group, smallcell carcinoma was more commonly detected in
participants with positive results than in those
with negative results, whereas in the radiography group, it was more commonly diagnosed in
participants with negative screening tests than
in those with positive results.

Discussion
At the T1 and T2 incidence screenings in the
NLST, the percentage of positive screening results in the low-dose CT group was more than
three times as high as that in the radiography
group. With low-dose CT, the number of lung
cancers that were detected by screening was increased by a factor of 2.7, and the number of interval lung cancers (diagnosed after a negative
screening) was decreased by 70%. The reduction
in lung-cancer mortality observed with low-dose
CT screening was coupled with a shift to detection of earlier-stage non–small-cell lung cancers
at incidence screenings.
In the low-dose CT group, 27.9% of all results
at the T1 screening and 16.8% of all results at
the T2 screening were positive; 2.4% and 5.2%
of positive screening tests were associated with
a lung-cancer diagnosis, respectively. The higher
positive predictive value at T2 is partly due to the
fact that a nodule observed to be stable over
three consecutive screenings could be interpreted as “negative” at the last screening.
Although this analysis does not address the
unique features of nodules that distinguish lung
cancers from noncancers, some preliminary observations can be made. With low-dose CT, the
positive predictive value increased as nodule size
increased up to 30 mm; this pattern was less
pronounced with radiography. For lesions larger
than 30 mm, the positive predictive value did not
n engl j med 369;10

reliably increase in either group, possibly because of misinterpretation of pneumonia as a
positive screening result. Moreover, nodules in
some size categories in the radiography group
were few in number, resulting in large uncertainties (confidence intervals) in the estimates of
positive predictive value.
In both groups, more lung cancers were diagnosed at T2 than at T1. It is likely that many
positive screening results at T0 were ultimately
diagnosed as lung cancer at T2, after observation of growth over time. Also, because T2 was
the final screening round in the trial, abnormalities detected in that round may have been followed more aggressively than those detected at
earlier rounds.
The performance characteristics of low-dose
CT are influenced by the risk (pretest probability)
of lung cancer among persons who undergo
screening. Given the low proportion of lung
cancers in participants 55 to 59 years of age who
underwent screening, increasing the minimum
age for screening may have merit; however,
other risk factors, in addition to age, need to be
considered in order to obtain the greatest possible benefit of screening.12 As our knowledge
evolves, screening guidelines will be informed
by integrating multiple demographic and clinical risk factors, measures of field injury such as
airflow obstruction, and validated biomarkers of
lung-cancer predisposition, measured in blood
or other readily accessible specimens.13-15
The performance of low-dose CT is also
influenced by the definition of positive screening results, which will be refined in light of
the experience of the NLST as well as other
randomized trials and single-group studies. In
the NLST, screening interpretations were di
chotomous. Other ongoing randomized trials,
including the Danish Lung Cancer Screening
Trial (ClinicalTrials.gov number, NCT00496977)
and the Dutch–Belgian Randomised Controlled
Trial for Lung Cancer Screening in High-Risk
Subjects (NELSON; Current Controlled Trials
number, ISRCTN63545820), have added an “in
determinate” interpretation category for nodules
between the lower (negative) and upper (positive)
size thresholds, with CT repeated at 3 months
to classify the findings as negative or positive.16,17
This two-step approach has little effect on overall
medical resource utilization, since patients with
nodules within this indeterminate size range typ
ically undergo early repeat low-dose CT; however,
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the change in classification significantly improves the positive predictive value of low-dose
CT screening relative to that observed in the
NLST. More important, the designation of “indeterminate” provides a more realistic representation of the risk of lung cancer for both patient
and provider, given that the majority of such
nodules are ultimately benign.
Increasing the minimum size threshold for
positive screening tests can also reduce the frequency of the diagnostic workup.18 In the NLST,
nodules that were 4 to 6 mm in diameter accounted for roughly half the positive screening
results with low-dose CT at both time points,
but such nodules were associated with lung cancer in less than 1% of participants. Future efforts to develop diagnostic prediction models in
this rapidly moving field should be informed by
aggregating data on nodule size from all screening trials; these efforts should balance the effects of test performance at a given nodule size
with potential delays in diagnosis and effects on
a reduction in mortality. The size threshold of a
nodule that indicates a positive screening, whether based on diameter or computer-assisted volumetric analysis,19,20 will vary depending on the
level of risk of lung cancer and must be assessed
in the context of the specific cohort undergoing
screening.
The NLST had a number of limitations. First,
the results may have been influenced by the
healthy-volunteer effect, although this effect
would be similar in the two screening groups.1
Second, in this analysis, data on medical resource
utilization was restricted to participants with
positive screening results. Our data underestimate the numbers of additional procedures and
attendant risks that could result from reported
findings other than those related to potential
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lung cancer. Data on these findings have been
collected in a subgroup of NLST participants
but are not reported here. Finally, the NLST
included three annual screenings.1 The results
of ongoing randomized trials in Europe and
mathematical modeling will help to inform the
effects of additional years of screening or different screening intervals on stage shift and
mortality reduction.
The two incidence screenings in the NLST
provide evidence that in a high-risk cohort, annual screening with low-dose CT detects more
lung cancers than radiography and results in a
stage shift toward early-stage, non–small-cell
lung cancers, which are potentially curable. The
performance characteristics of low-dose CT may
be enhanced by determining the most appropriate risk cohort, refining both algorithms for
interpreting the results of screening and definitions of positive findings, and determining the
appropriate duration and timing of screening.
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